Jann Michael W, Hon Yuen Yi, Shamsi Shahab A, Zheng Jack, Awad Eric A, Spratlin Vicky
Department of Clinical and Administrative Sciences, Mercer University, Southern School of Pharmacy, Atlanta, Georgia 30341, USA.
Pharmacotherapy. 2006 May;26(5):627-33. doi: 10.1592/phco.26.5.627.
To investigate the potential drug-drug interaction between lamotrigine, an antiepileptic agent used to treat bipolar disorders, and olanzapine, an atypical antipsychotic drug also used to treat bipolar disorders, both of which are metabolized by the uridine diphosphate glucuronosyltransferase system.
Prospective cohort study.
University center for clinical research.
Fourteen nonsmoking, healthy volunteers.
Subjects received lamotrigine 25 mg/day for 5 days, then 50 mg/day for 10 days to achieve steady-state concentrations. On day 15, blood samples were obtained before and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours after the dose. Lamotrigine 50 mg/day was then given for an additional 3 days. On the next day, lamotrigine 50 mg and olanzapine 5 mg were coadministered. Blood samples were obtained at the same times as before and at 48, 72, and 96 hours after dosing.
Blood samples were assayed for lamotrigine and olanzapine concentrations by means of high-performance liquid chromatography. Olanzapine did not significantly affect lamotrigine disposition, as we observed no differences in the area under the concentration-time curve from 0-24 hours or in lamotrigine plasma concentrations at baseline or at 24 hours. For lamotrigine, the mean time to reach maximum concentration was significantly prolonged during olanzapine coadministration (mean +/- SD 1.9 +/- 1.3 vs 4.0 +/- 3.0 hrs, p = 0.025), possibly because of the anticholinergic properties associated with olanzapine. Mild sedation was the only adverse effect that occurred during lamotrigine and olanzapine coadministration.
Lamotrigine and olanzapine can safely be combined in healthy volunteers at the low doses studied, without a clinically significant interaction. When prescribing high doses of olanzapine and lamotrigine for bipolar disorder, patients must be carefully monitored.
探讨用于治疗双相情感障碍的抗癫痫药物拉莫三嗪与同样用于治疗双相情感障碍的非典型抗精神病药物奥氮平之间潜在的药物相互作用,这两种药物均通过尿苷二磷酸葡萄糖醛酸基转移酶系统代谢。
前瞻性队列研究。
大学临床研究中心。
14名不吸烟的健康志愿者。
受试者先接受5天每天25毫克的拉莫三嗪治疗,然后10天每天50毫克以达到稳态浓度。在第15天,给药前及给药后0.5、1、2、3、4、6、8、10、12和24小时采集血样。然后再给予3天每天50毫克的拉莫三嗪。次日,同时给予50毫克拉莫三嗪和5毫克奥氮平。在与之前相同的时间点以及给药后48、72和96小时采集血样。
采用高效液相色谱法测定血样中拉莫三嗪和奥氮平的浓度。奥氮平对拉莫三嗪的处置无显著影响,因为我们观察到0至24小时浓度-时间曲线下面积以及基线或24小时时拉莫三嗪血浆浓度均无差异。对于拉莫三嗪,在联合使用奥氮平期间达到最大浓度的平均时间显著延长(平均±标准差1.9±1.3小时对4.0±3.0小时,p = 0.025),这可能是由于奥氮平的抗胆碱能特性。轻度镇静是拉莫三嗪与奥氮平联合使用期间唯一出现的不良反应。
在本研究的低剂量下,拉莫三嗪和奥氮平可在健康志愿者中安全联用,无临床显著的相互作用。为双相情感障碍患者开具高剂量奥氮平和拉莫三嗪时,必须仔细监测患者情况。